3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Neoplasms
1
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
80
Nivolumab
60
Sunitinib
59
Sorafenib
36
Everolimus
32
pazopanib
30
Axitinib
27
cabozantinib
25
Ipilimumab
24
Bevacizumab
24
atezolizumab
20
belzutifan
19
lenvatinib
16
avelumab
13
Paclitaxel
10
Docetaxel
9
temsirolimus
8
Cyclophosphamide
8
spartalizumab
7
fludarabine
7
Interleukin-2
7
Interferon alpha-2
7
tivozanib
6
durvalumab
6
Cetuximab
6
cemiplimab
5
aldesleukin
5
Ramucirumab
5
CB-839
5
bempegaldesleukin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Renal Cell
×
bexmarilimab
×
Clear all
NCT05104905
2022-05-11
RENACOL
Faron Pharmaceuticals Ltd
Phase 1/2
Withdrawn